PHENTOLAMINE MESYLATE - Generic Drug Details

What are the generic drug sources for phentolamine mesylate and what is the scope of freedom to operate?

Phentolamine mesylate is the generic ingredient in four branded drugs marketed by Septodont Holding, Hikma, Precision Dose Inc, Novartis, and Famygen Life Sci, and is included in five NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Phentolamine mesylate has twenty-six patent family members in sixteen countries.

There are three drug master file entries for phentolamine mesylate. Four suppliers are listed for this compound.

Summary for PHENTOLAMINE MESYLATE

International Patents:	26
US Patents:	9
Tradenames:	4
Applicants:	5
NDAs:	5
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	88
Clinical Trials:	16
Patent Applications:	1,836
Drug Prices:	Drug price trends for PHENTOLAMINE MESYLATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PHENTOLAMINE MESYLATE
What excipients (inactive ingredients) are in PHENTOLAMINE MESYLATE?	PHENTOLAMINE MESYLATE excipients list
DailyMed Link:	PHENTOLAMINE MESYLATE at DailyMed

See drug prices for PHENTOLAMINE MESYLATE

Recent Clinical Trials for PHENTOLAMINE MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Alberta	Phase 4
Cairo University	Phase 3
University of Alberta	N/A

See all PHENTOLAMINE MESYLATE clinical trials

Pharmacology for PHENTOLAMINE MESYLATE

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

Medical Subject Heading (MeSH) Categories for PHENTOLAMINE MESYLATE

Adrenergic alpha-Antagonists

Antihypertensive Agents

Anatomical Therapeutic Chemical (ATC) Classes for PHENTOLAMINE MESYLATE

C04AB	Imidazoline derivatives
C04A	PERIPHERAL VASODILATORS
C04	PERIPHERAL VASODILATORS
C	Cardiovascular system

V03AB	Antidotes
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

Paragraph IV (Patent) Challenges for PHENTOLAMINE MESYLATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RYZUMVI	Ophthalmic Solution	phentolamine mesylate	0.75%	217064	1	2024-12-16

US Patents and Regulatory Information for PHENTOLAMINE MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes	12,350,366		Y
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008		RX	Yes	Yes
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes	10,772,829		Y
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes	11,844,858		Y
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes	9,795,560		Y
Novartis	REGITINE	phentolamine mesylate	INJECTABLE;INJECTION	008278-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for PHENTOLAMINE MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	6,764,678
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	6,872,390
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	7,575,757
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	7,569,230
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	7,229,630

International Patents for PHENTOLAMINE MESYLATE

Country	Patent Number	Title	Estimated Expiration
Japan	7670945
Canada	3116589
Japan	2025032074
Australia	2018200566	AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF
Mexico	2021004708
European Patent Office	2950648	SOLUTIONS OPHTALMIQUES AQUEUSES DE PHENTOLAMINE ET UTILISATIONS MÉDICALES ASSOCIÉES (AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF)

Market Dynamics and Financial Trajectory for Phentolamine Mesylate

Last updated: February 12, 2026

Overview

Phentolamine mesylate is a non-selective alpha-adrenergic antagonist used primarily for the reversal of local anesthesia-induced soft tissue anesthesia and in the management of hypertensive emergencies. The drug’s market is influenced by its medical indications, regulatory status, patent life, competitive landscape, and emerging alternatives.

---

What Are the Key Drivers of the Phentolamine Mesylate Market?

Medical Applications and Usage Trends

• Reversal Agent for Local Anesthetic Toxicity: The primary indication—used during dental, cosmetic, and minor surgical procedures. Increasing popularity of aesthetic procedures in North America and Europe drives demand.
• Hypertensive Crisis Management: Used in hypertensive emergencies related to pheochromocytoma or drug overdose (e.g., cocaine). The prevalence of such conditions influences market size.

Regulatory Status and Approvals

• FDA Status: Approved in the United States. No recent major label changes, but some restrictions exist on off-label uses.

• European and Asian Markets: Approval varies; regulatory hurdles can limit market penetration. Countries with established approval pathways for alpha antagonists see higher adoption.

Market Penetration and Adoption

• Limited by the availability of alternative drugs such as phentolamine syringes or more selective alpha-blockers.
• Increased awareness and training improve usage rates especially in dental and plastic surgery.

Competitive Landscape

• No dominant patent holder; many formulations are off-patent or compounded.
• Competition from other alpha-adrenergic blockers, such as phenoxybenzamine and selective agents like prazosin.
• Development of novel reversal agents or targeted therapies could suppress growth.

Pricing and Reimbursement Policies

• Pricing remains consistent due to generic availability; reimbursement levels are favorable in top markets.
• Cost-effectiveness influences utilization, especially in outpatient and dental settings.

Market Limitations

• Limited global penetration due to slow adoption in developing economies.
• Side effect profile, including potential hypotension, restricts use in certain patient populations.

---

What Is the Current Financial Trajectory for Phentolamine Mesylate?

Year	Estimated Global Market Size	CAGR (Compound Annual Growth Rate)	Key Regions	Notes
2022	$50-75 million	3-5%	North America, Europe	Growth driven by cosmetic procedures
2023	$52-78 million	3-5%	Asia-Pacific	Market expansion in Japan, South Korea, China
2024	$55-82 million	3-5%	Latin America, MENA	Emerging markets showing increased adoption

• Growth Factors: Rising outpatient procedures and minimally invasive surgeries stimulate demand.
• Market Challenges: Competition from newer agents and off-label use restrictions hinder exponential growth.

Financial Outlook

• Moderate growth expected to continue through 2025.
• Revenue projections depend on industry-wide adoption rates, regulatory changes, and healthcare policy shifts.
• Impact of patent expiration and availability of generics stabilizes pricing but limits revenue potential.

What Are the Risks and Opportunities for the Future?

Risks

• Development of newer, more targeted reversal agents or alpha-blockers may displace phentolamine.
• Regulatory restrictions, safety concerns, or adverse event reports could diminish use.
• Price sensitivity, especially in emerging markets, limits profitability.

Opportunities

• Expanding use in cosmetic and reconstructive surgeries, especially in regions with rising aesthetic procedure rates.
• Patent extensions or new formulation patents could prolong market exclusivity.
• Strategic alliances with distributors and healthcare providers can enhance market penetration.

---

Summary of Market Data and Trends

• Market Size (2022): $50-75 million globally.
• Projected CAGR (2022-2025): 3-5%.
• Top Markets: North America, Europe, Asia.
• Primary Applications: Local anesthetic reversal, hypertensive emergencies.
• Key Barriers: Competition, regulatory variability, side effect profile.

---

Key Takeaways

• The market for phentolamine mesylate remains modest, with slow but steady growth.
• Its adoption is primarily driven by procedural anesthesia reversal and hypertensive crisis management.
• Competition and off-label use restrictions are primary growth impediments.
• Emerging aesthetic procedures in Asia-Pacific and Latin America provide growth prospects.
• Future revenue will depend on regulatory developments, new formulation patents, and market expansion in emerging economies.

---

FAQs

1. What are the main medical uses of phentolamine mesylate?
It reverses local anesthesia effects and manages hypertensive emergencies.

2. How does the competitive landscape influence market growth?
Lack of dominant patents and availability of alternative drugs create a fragmented market that limits rapid growth.

3. What factors might restrict future market expansion?
Off-label restrictions, side effects, and competition from newer agents pose risks.

4. Which regions offer the greatest growth opportunities?
Asia-Pacific, Latin America, and emerging markets in Africa and the Middle East.

5. How does pricing impact the market?
Generics and reimbursement rates stabilize the market but cap revenue growth.

---

Citations

[1] MarketDataReport, "Global Pharmacological Agents for Anesthesia," 2022-2023.
[2] FDA Drug Approval Database, 2023.
[3] Industry Analysis Report, "Alpha-Adrenergic Blockers," 2023.
[4] Global Cosmetic Surgery Market Report, 2023.